EP0594260A1 - Nucleic acid material amplification and detection - Google Patents

Nucleic acid material amplification and detection Download PDF

Info

Publication number
EP0594260A1
EP0594260A1 EP93202962A EP93202962A EP0594260A1 EP 0594260 A1 EP0594260 A1 EP 0594260A1 EP 93202962 A EP93202962 A EP 93202962A EP 93202962 A EP93202962 A EP 93202962A EP 0594260 A1 EP0594260 A1 EP 0594260A1
Authority
EP
European Patent Office
Prior art keywords
wash
compartment
detection site
label
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93202962A
Other languages
German (de)
French (fr)
Other versions
EP0594260B1 (en
Inventor
Paul Hong-Dze c/o EASTMAN KODAK COMPANY Chen
John Bruce C/O Eastman Kodak Company Findlay
Susan Melissa c/o EASTMAN KODAK COMPANY Atwood
Lynn C/O Eastman Kodak Company Bergmeyer
John Benjamin c/o EASTMAN KODAK COMPANY Chemelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Diagnostic Systems Inc
Original Assignee
Eastman Kodak Co
Johnson and Johnson Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/979,569 external-priority patent/US5422271A/en
Application filed by Eastman Kodak Co, Johnson and Johnson Clinical Diagnostics Inc filed Critical Eastman Kodak Co
Publication of EP0594260A1 publication Critical patent/EP0594260A1/en
Application granted granted Critical
Publication of EP0594260B1 publication Critical patent/EP0594260B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/505Containers for the purpose of retaining a material to be analysed, e.g. test tubes flexible containers not provided for above
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0481Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers

Definitions

  • This invention relates to nucleic acid material amplification and detection and is more particularly concerned with reaction cuvettes or devices, and methods, used to amplify and detect such materials.
  • DNA detection is described in EP-A-0 381 501 using a method wherein polymerase chain reaction (PCR) amplification of miniscule amounts of nucleic acid material, and detection of the amplified material can all occur in a single cuvette which keeps the amplified material from escaping.
  • PCR polymerase chain reaction
  • Six temporarily-sealed blisters, also called compartments, are provided along with passageways connecting them to a detection site in a detection compartment.
  • the blisters provide, in order, a PCR reaction compartment; a first wash compartment; an enzyme-labeling compartment containing, for example, streptavidin horseradish peroxidase (hereinafter SA-HRP); a second wash compartment; a compartment containing signalling material responsive to the enzyme; and a stop solution compartment.
  • SA-HRP streptavidin horseradish peroxidase
  • the Roche procedure incubates "at 37°C for 15 minutes with an avidin-horseradish peroxidase conjugate", which of course corresponds to the emptying of the enzyme blister of the cuvette described in EP-A-0 381 501 for the very same purpose. Thereafter, the Roche procedure" again washed the plate four times" "to remove unbound conjugate.” This, of course, corresponds to the second wash step provided by the second wash blister disposed between the enzyme blister and the signalling material blister in the cuvette of EP-A-0 381 501.
  • non-specific signal that is, signal which occurs because of either the presence of unbound nucleic acid material which is not the target, and/or unbound SA-HRP which should not be present because the target nucleic acid material is not present.
  • a method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal, characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between.
  • a device for amplifying and detecting nucleic acid material by using at least one target strand as a template comprising:- a reaction compartment for amplifying a sample of nucleic acid material; a detection site for detecting amplified nucleic acid material; storage compartments containing a label and signalling material effective to generate, in combination, a detectable signal, and passageways for fluidly connecting the reaction compartment and storage compartments with the detection site; characterized in that the device further includes no more than one wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments, and no more than one passageway connecting the wash compartment to the detection site so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments to the detection site.
  • the invention is useful regardless of whether PCR amplification is used or not, and regardless of the presence of all the features of that cuvette, provided that no more than one wash compartment is included with no more than one intervening wash step as a result.
  • wash or “wash solution” means, a solution substantially free of capture, label and signal-forming reagents used in the other compartments, that is, in either the label compartment or the signalling material compartment.
  • each slug of liquid passes over the detection site(s), improving the efficiency.
  • the optional shear-thinning gel which can be added as described hereinafter enhances this capability, in that it appears to create a more viscous slug which retards backward migration of the components that are removed by the slug's front boundary.
  • FIG. 1 illustrates one form of this invention, in which the wash compartment and wash step in between the reaction compartment and the label compartment has been eliminated.
  • a reaction cuvette or device 10 comprises an inlet port 22 for injection of patient sample liquid, which connects via a passageway 21 to a PCR reaction compartment 26.
  • a seal 46 temporarily blocks flow out of compartment 26. When seal 46 is broken, liquid feeds via a passageway 44 to a detection chamber 40 having sites 41 comprising, preferably, beads anchored in place which will complex with any targeted analyte passing them from compartment 26, and then with reagents coming from the other reagent compartments.
  • Those other compartments are compartments 30, 32, 34, each feeding via passageways 48 and 50 to chamber 40. Each of those passageways is temporarily sealed at 56, and contains an appropriate reagent liquid.
  • the wash compartment preferably comprises a buffer, surfactants, EDTA, NaCl, and other salts.
  • Compartment 26 in addition to the patient sample added by the user, preferably includes all the conventional reagents needed for PCR amplification, optionally kept in place by temporary seal 25.
  • the reagents can be pre-incorporated, or added with the patient sample as the latter is introduced.
  • the reagents include primers which are bound to one member of a binding pair, the other member of which appears in compartment 30 described below.
  • a useful example of the binding member attached to a primer is biotin. (If present, Seal 25 is burst by injecting sample.)
  • Compartment 30 comprises, preferably, a label such as an enzyme bound to a complexing agent, such as avidin, which is a member of a binding pair, the other member of that pair being bound to a primer which becomes part of a targeted analyte during amplification in the reaction compartment 26 as described above.
  • a useful reagent in compartment 30 is streptavidin horseradish peroxidase (hereinafter, SA-HRP). The other member of that binding pair is then biotin.
  • Labels other than enzymes are also useful.
  • fluorescent, radioactive, and chemiluminescent labels are also well-known for such uses.
  • Chemiluminescent labels also preferably use a compartment 34 containing signalling reagent, discussed below for enzyme labels.
  • Compartment 32 preferably comprises a wash solution as the reagent.
  • Compartment 34 preferably comprises signalling material, and any dye stabilizing agent which may be useful.
  • a useful reagent solution in compartment 34 is a solution of a leuco dye which is a conventional substrate for the enzyme of compartment 30. H2O2 and any shear-thinning gels are also included.
  • Compartment 42 is a waste-collecting compartment, optionally containing an absorbant.
  • Roller 60 exemplifies the exterior pressure means used to burst each of the compartments sequentially, to sequentially advance the contents of the respective compartment to detection chamber 40. Because all of the compartments and passageways remain sealed during the processing, no leakage out of the device occurs and carry-over contamination is prevented. Sealing of port 22 is achieved by folding corner 70 about fold line 72, so that hole 74 fits over port 22 and passageway 21 is pinched off. A closure cap is then used to keep corner 70 so folded.
  • a useful processor to process device 10 is shown in EP-A-0 402 994.
  • Such a processor uses a support surface on which devices 10 are placed in an array, and pressure members, for example, rollers, are mounted in position to process each of the cuvettes in parallel.
  • the rollers are journalled several to one or more axles for convenience, these axles being incrementally advanced by gearing.
  • the support surface is horizontal or tilted up to 15° from horizontal.
  • heaters can be optionally included, either in stationary form or carried with the rollers.
  • one and only one wash compartment 32 is used, to provide a wash step after incubation of the SA-HRP at the sites 41 of compartment 40, to remove any unbound SA-HRP. It is thought that no wash step or wash liquid needs to be provided between the respective sequential movements of the amplified nucleic acid material and the SA-HRP, to sites 41, for the reason that each reagent directed to the detection site is effectively washed out by the next reagent entering the station. It is surprising that the small volume in each compartment is adequate to do this.
  • the wash compartment can be supplemented, if desired, with additional wash liquid.
  • Figure 2 is to add a wash compartment adjacent to the first wash compartment, so that initially the first wash compartment is emptied to the detection site, and then the second wash compartment. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "A" is appended.
  • cuvette 10A involves the exact same features as in the embodiment of Figure 1, except that an additional temporarily-sealed compartment 36 of wash liquid is interposed between compartments 32A and 34A. Passageway 52 connects it to compartment 40A, after seal 56A of compartment 36 is burst.
  • a single wash compartment but with a greater volume of wash can be used.
  • cuvette 10B comprises all the features of the previously described embodiments, except there is no wash compartment at all.
  • the only compartments are the thermal cycling reaction compartment 26B, the label-containing compartment 30B (with, for example, streptavidin horseradish peroxidase, and compartment 34B containing the signalling material, for example, H2O2, optionally a shear-thinning gel described immediately hereafter, and a leuco dye which reacts with the label enzyme to produce a dye.
  • seals 46B and 56B are burst sequentially by roller 60B, the contents empty via passageways 44B and 48B, respectively, into detection site 40B and then into waste compartment 42B.
  • an optional ingredient for inclusion with the signalling material is an approximate 0.5% agarose solution, to stabilize color formation at the detection sites in the detection compartment.
  • Agarose has the shear thinning behavior that its viscosity at about this concentration drops 270mPas (27 poise) between a shear rate of 1 to 102s ⁇ 1 (more than 60% of its drop), and only another 30mPas (3 poise) for rates above 102s ⁇ 1, when measured at 40°C.
  • Other shear-thinning gels of similar viscosity behavior and low percentage concentration can also be used.
  • an enlarged detection site 41B comprising immobilized beads as described in the aforesaid EP-A-0 381 051.
  • the amplified target nucleic acid material with a biotin tail is shown as " ⁇ B ".
  • SA-HRP is shown as "A*" as a labeled avidin.
  • HUT/AAV/78 cells containing one copy of HIV per cell were treated in a standard phenol chloroform extraction process to isolate the DNA, and the amount of DNA obtained was quantified on a spectrophotometer.
  • the recovered DNA (100,000 copies HIV) was amplified by polymerase chain reaction (PCR) in a cocktail containing each of the primers identified below (1 ⁇ M each), buffer [10mM magnesium chloride, 50mM tris(hydroxymethyl)aminomethane (TRIS), 50mM potassium chloride, and 0.1mg/ml gelatin], 1.5mM of each of dATP, dCTP, dGTP, and dTTP deoxynucleotide triphosphates, and 40 units of DNA polymerase obtained from Thermus aquaticus .
  • PCR polymerase chain reaction
  • Two sets of primers were used, one set complementary to the ENV region, and one set complementary to the GAG region of the HUT/HIV DNA, as is known to be used in multiplexing.
  • One primer in each set was biotinylated to facilitate detection.
  • PCR protocol was carried out using 250 ⁇ l of the above cocktail in the PCR reaction blisters of PCR analytical elements of the type described in EP-A-0 381 051 and US-A-5 299 297. More specifically, the cuvette 10C of Figure 7 was used. Parts similar to those previously described bear the same reference numeral with the letter “C” appended. Thus, compartments 26C, 30C, 32C, 36C and 34C; passageways 44C, 48C, 50C and 52C; detection site 40C, and waste compartment 42C were used as described above, except for the layout, or as noted hereinafter. For one thing, PCR amplification was done in a cuvette separate from the test cuvette 10C, with the amplified material being pooled and then injected into compartment 26C for consistency of results in all replicates, for example, 32 in Example 1.
  • a thermal cycling processor of the type described in EP-A-0 402 994 was used.
  • the target DNA was preheated to 90°C for 10s, then denatured at 96°C for 30s and cooled to 70°C for 60s to anneal primers and produce primer extension products. The latter two steps (heating at 96°C, then 70°C) were repeated for a total of 40 cycles.
  • This PCR process was replicated 64 times, and the fluid containing the newly made PCR product was transferred from the 64 PCR blisters into a common vessel to create a pool of PCR product. Samples from this pool were diluted 1:20 in the PCR buffer described above for use in the tests described hereinafter.
  • a wash solution was prepared to contain 1% sodium decyl sulfate in phosphate buffered saline solution containing 10mmolar sodium phosphate, 150mmolar sodium chloride, and 1mmolar ethylenediaminetetraacetic acid, pH 7.4.
  • a conjugate of streptavidin and horseradish peroxidase obtained from Zymed Labs (San Francisco, CA) was diluted 1:8000 with casein (0.5%) in a phosphate buffer solution (pH 7.3) containing thimerosal preservative (0.01%).
  • a solution of 25 g of polyvinylpyrrolidone in 100ml of water was mixed with a solution of 0.20g of 4,5-bis(4-dimethylaminophenyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)imidazole blue-forming leuco dye in 1ml N,N-dimethylformamide and stirred for 1 hour.
  • a poly[styrene-co-3-(p-vinylbenzylthio)propionic acid] (mole ratio 97.6:2.4, weight ratio 95:5, 1 ⁇ m average diameter) aqueous polymer particle dispersion was prepared, and an oligonucleotide described hereinafter was covalently bound to one portion of the polymer particles, and another oligonucleotide was covalently bound to another portion of the polymer particles using the procedures described in US-A-5 149 737 and in EP-A-0 462 644.
  • the oligonucleotides were linked to the polymer particles through two tetraethylene glycol spacers, a 3-amino-1,2-propanediol moiety, and a thymine base. Each oligonucleotide was appended to the polymer particles through the amino group of the 3-amino-1,2-propanediol moiety to form reagents by the procedures of US-A-4 962 029.
  • the polymer/oligonucleotide particle probes were mixed with a latex adhesive of poly(methyl acrylate-co-sodium 2-acrylamido-2-methylpropanesulfonate-co-2-acetoacetoxyethyl methacrylate) (90:4:6 weight ratio) at a dry weight ratio of particles to adhesive polymer of 4/0.1 (2.5% adhesive).
  • the aqueous dispersion had a solids content of 4%.
  • control reagent oligonucleotide sequence is a sequence from the HIV genome and was employed as a nonsense sequence. This nonsense probe should not capture any of the HUT/HIV analyte sequences, and consequently, no dye development should occur on the control reagents.
  • the other probe reagent sequence was complementary to a sequence in the ENV region of the HUT/HIV DNA.
  • the above reagents were used to prepare a series of analytical elements (cuvettes), each having reagent compartments (one of which is a PCR reaction blister into which the sample analyte is first introduced) a detection compartment, and a waste reservoir.
  • the analytical devices were prepared by heating a sheet of poly(ethylene terephthalate)/polyethylene laminate (SCOTCHPAKTM 241, 3M Co.) at a forming station (or mold) to form an array of depressed areas (blisters) toward one side of the sheet, and a larger depressed area near the end, and at the other side of the sheet, to which a main channel ultimately leads, a main channel from the first blister to the last, and tributary channels from each blister to the main channel so that upon lamination to a cover sheet at a later time, the resulting cuvette had narrow channels leading from the depressed areas to a main channel analogous to the devices described in US-A-5 299 297.
  • Each depressed area except the one at each end of the main channel was filled with an appropriate reagent composition.
  • a cover sheet was laminated to form a cover over the depressed and channel areas, and sealed to create a burst seal between each depressed area (except the last one) and the channel leading from it to the main channel.
  • the cover sheet was treated overall with corona discharge.
  • the probe reagent formulations described above were then immediately deposited in four alternating spots on the treated surface, each spot having 0.9 to 1.1 ⁇ l of formulation noted hereinafter, in a row.
  • the disposed formulations were dried for 30s in a stream of air at room temperature while heating the opposite side of the support with an iron at about 95°C.
  • the cover sheet was then laminated and sealed in three steps.
  • the sandwich was pressed and sealed by heating at about 149°C only around the blisters containing the reagent solutions and around the waste blister.
  • the formation of the sample-receiving PCR blister, including burst seals, and the channels was completed by heating the test pack between appropriately shaped heating jaws at about 163°C.
  • the third step was the formation of perimeter seals around the test pack, and resealing all blister perimeter seals using a top plate temperature of 199°C while the bottom plate remained at ambient temperature.
  • the channels and blisters formed in the completed test pack (or element) were located so that passage of a roller across the portion of the element containing the reagent blisters would sequentially burst the seals of the blisters and force the reagent from each blister into and along an exit channel to the main channel leading to the area containing the capture probes.
  • the finished element was inverted so that the cover sheet containing the capture probe spots (deposits) is the bottom of the finished element with the probe deposits properly aligned in the main channel to form a detection station.
  • the four probe spots were located in different positions of the main channel in several samples.
  • a last waste compartment located at the end of the main channel was larger than the others and fitted with an absorbent to be a reservoir for waste fluids, for both Example 1 and the Comparative Example.
  • Example 1 The completed cuvettes of Example 1 and the Comparative Example were used to evaluate the reagent formulations as follows: A blister in each test device was filled (190-210 ⁇ l) with a 20X dilution of the PCR product described above and processed as follows:
  • the analyte was preheated to 95°C for 120s and its blister rolled to break the seal and advance the solution to the detection station (probe deposits).
  • the analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the SA-HRP conjugate in the second blister was preheated to 65°C.
  • the conjugate blister was rolled, the seal broken, and the solution directed to the detection area to displace the analyte.
  • the third blister containing the first wash solution preheated to 55°C was broken and the wash directed to the detection station and held there for 5min while the second wash solution was preheated to 55°C. Then the blister containing the second wash solution was broken and the wash directed to the detection station.
  • the blister containing the dye signal-forming composition was rolled without preheating, and the seal broken, and the composition directed to the detection station where the color scores were read after a 5min incubation period using a color chart as described hereinbelow.
  • the color scores are recorded in Table I and presented graphically in Figure 5A.
  • the blister containing the analyte in each element was preheated to about 95°C for 120s and then rolled to break the seal and advance the solution to the area containing the four immobilized deposits of probe reagents, that is, the two control probes and the two HUT/HIV probes deposited with adhesive.
  • probe reagents that is, the two control probes and the two HUT/HIV probes deposited with adhesive.
  • the analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the blister containing the wash solution was preheated to 55°C. Then the wash solution blister was rolled to break the seal and direct the wash solution into the detection area to clean out the main channel and to remove unbound analyte from the detection area.
  • the seal of the streptavidin/horseradish peroxidase conjugate blister was rolled and broken and the solution directed to the detection area where it binds to the immobilized biotinylated analyte over a 5min period.
  • the second wash composition was preheated to 55°C, and the seal of the blister was then broken with the roller and directed to the detection station where it displaced the unbound label.
  • the seal of the dye signal-forming composition in the last blister was broken with the roller, and the fluid directed to the detection station where it displaced the second wash solution.
  • Dye formation on the probe deposits was allowed to proceed for 5 minutes before reading color density scores. The color of each probe deposit was evaluated by comparison of the wet dye density with a color chart where 0 is no density and 10 is the highest density. The color scores are recorded in Table II and presented graphically in the graph of Figure 5B.
  • Example 1 HIV REPLICATE LTR ENV LTR ENV 1 0.5 7 0.5 6.5 2 0 6.5 0 4 3 0.5 6.5 0.5 6.5 4 1 6.5 1 6.5 5 1 6.5 1 6.5 6 0.5 6.5 0.5 6 7 0.5 5 0.5 5.5 8 0.5 6.5 0.5 6 9 1 5 1 4 10 0.5 5 0.5 5 11 0.5 7 0.5 6.5 12 0.5 6 0.5 6 13 0.5 7 0.5 6.5 14 0.5 6 0.5 7 15 0.5 2 0 2 16 0.5 7 0.5 6.5 Average 6.0 5.69 TABLE II Comparative Example - HIV REPLICATE LTR ENV LTR ENV 1 0.5 5 0.5 5.5 2 0.5 2 0.5 6 3 0.5 6.5 0.5 5.5 4 1 6 1 6 5 0.5 2 0.5 2 6 1 7 1 6 7 1 7 1 5 8 1 7 1 6 9 1 3 1 7 10 1 7
  • Two sets of PCR analytical cuvettes were prepared by the procedures of Example 1 with the following exceptions: 1.
  • a third probe composition was prepared by the procedures of Example 1 to contain a sequence complementary to a sequence from the GAG region of the HUT/HIV DNA. 2. Only one spot (deposit) of each of the 3 probes was incorporated in each element, in the order of (1) new probe from the GAG region as described above, (2) control probe of Example 1, and (3) reagent probe of Example 1. 3.
  • One set of cuvettes was 5-blister cuvettes in the reverse wash format of Example 1 (SA-HRP conjugate in the second blister and wash in the third blister), and the cuvettes in that set were processed as described in Example 1. 4.
  • the second set of cuvettes used only 3 reagent compartments and no wash compartments, as shown in Figure 3. They contained the same compositions, including the analyte composition from the pool, and same amounts as the corresponding compositions in the first set of elements of Example 1 (the set with the conventional wash format), and the blisters were in the following order: Blister ( Figure 7) Content 26C PCR analyte 30C SA-HRP 32C Dye-forming detection composition
  • the cuvettes in the second set were processed as follows: The analyte in the PCR blister was preheated to 95°C for 120s, and the blister was rolled to break the seal and direct the analyte to the 3 probe deposits in the detection station. Hybridization at 42°C was allowed to proceed for 5min while the SA-HRP solution in the second blister was preheated to 65°C. The second blister was then rolled to break the seal and the solution directed through the channels to the detection station. The conjugate was incubated over the detection station for 5min, then the blister containing the dye-forming detection dispersion was rolled without preheating to break the seal and direct the dispersion to the detection station to displace the SA-HRP.
  • the 3-blister configuration allows for use of less reagents, a smaller unit manufacturing cost, less cuvette storage space, shorter processing times, and a smaller, less complex processor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

It has been known to use more than one wash step during amplification and detection of nucleic acid material in a sealed cuvette. Described herein is an improved cuvette (10) and method for amplifying and detecting nucleic acid material in which no more than one wash step is utilised and which does not substantially adversely affect the results obtained.

Description

  • This invention relates to nucleic acid material amplification and detection and is more particularly concerned with reaction cuvettes or devices, and methods, used to amplify and detect such materials.
  • DNA detection is described in EP-A-0 381 501 using a method wherein polymerase chain reaction (PCR) amplification of miniscule amounts of nucleic acid material, and detection of the amplified material can all occur in a single cuvette which keeps the amplified material from escaping. Six temporarily-sealed blisters, also called compartments, are provided along with passageways connecting them to a detection site in a detection compartment. The blisters provide, in order, a PCR reaction compartment; a first wash compartment; an enzyme-labeling compartment containing, for example, streptavidin horseradish peroxidase (hereinafter SA-HRP); a second wash compartment; a compartment containing signalling material responsive to the enzyme; and a stop solution compartment. Each of these is caused to empty into the detection compartment in the order indicated, where a detection site is used to capture the amplified nucleic acid material and to generate a detectable signal.
  • The use of the two wash compartments to provide two wash steps is consistent with all conventional approaches to detecting nucleic acid material. For example, Vol. 30 of J. Clin. Microbiol. 845-853 (April, 1992) describes a process used by Roche (p. 846-847) as being one in which, following hybridization of biotinylated product to the solid wall surface, "we washed the plate 4 times with wash Buffer I to remove any unhybridized product". These four washes correspond to the first wash step of the first wash blister of the cuvette of EP-A-0 381 501, since there also, any DNA or nucleic acid material "unhybridized" to the detection sites is washed off. Thereafter, the Roche procedure incubates "at 37°C for 15 minutes with an avidin-horseradish peroxidase conjugate", which of course corresponds to the emptying of the enzyme blister of the cuvette described in EP-A-0 381 501 for the very same purpose. Thereafter, the Roche procedure" again washed the plate four times" "to remove unbound conjugate." This, of course, corresponds to the second wash step provided by the second wash blister disposed between the enzyme blister and the signalling material blister in the cuvette of EP-A-0 381 501.
  • Such procedures, with all the washes, although quite workable, are time consuming and therefore expensive. Further, the washes introduce complications into the manufacture of the cuvette. However, they have been considered essential in order to eliminate "non-specific signal," that is, signal which occurs because of either the presence of unbound nucleic acid material which is not the target, and/or unbound SA-HRP which should not be present because the target nucleic acid material is not present.
  • Thus, it has been a problem prior to this invention to come up with a detection sequence which eliminates at least one, and preferably both, of the wash steps and wash blisters heretofore needed, without causing so much noise in the detection as to make the signal unreliable.
  • It has been determined that the format of the cuvette used in the methods described in EP-A-0 381 501 lends itself to eliminating one or both of the wash blisters, while providing substantially the same result. This was particularly surprising, given the substantial history which has dictated that washes are an essential step.
  • More specifically, in accordance with one aspect of the present invention, there is provided a method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal,
       characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between.
  • As will be apparent, "either-or" used in this context is the non-exclusive use.
  • In accordance with another aspect of the present invention, there is provided a device for amplifying and detecting nucleic acid material by using at least one target strand as a template, the device comprising:-
       a reaction compartment for amplifying a sample of nucleic acid material;
       a detection site for detecting amplified nucleic acid material;
       storage compartments containing a label and signalling material effective to generate, in combination, a detectable signal, and
       passageways for fluidly connecting the reaction compartment and storage compartments with the detection site;
       characterized in that the device further includes no more than one wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments, and no more than one passageway connecting the wash compartment to the detection site so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments to the detection site.
  • Accordingly, it is an advantageous, unexpected feature of the invention that a method and device for amplifying and detecting nucleic acid material are provided which avoid at least one of the washes heretofore considered necessary to produce the desired result.
  • For a better understanding of the present invention, reference will now be made, by way of example only, to the accompanying drawings in which:-
    • Figure 1 is a plan view of one embodiment of a reaction device constructed in accordance with the present invention;
    • Figures 2 and 3 are plan views similar to that shown in Figure 1, but showing a second and third embodiment respectively of a device in accordance with the present invention;
    • Figures 4A to 4C are fragmentary sectioned views illustrating a postulated mechanism for the present invention;
    • Figures 5A to 5B and 6A to 6B are graphs showing repetitive color scores achieved during the practice of the invention (5A, 6A and 6B) or of a comparative example (5B); and
    • Figure 7 is a plan view similar to that shown in Figure 2, but showing a modified cuvette used for the working examples.
  • The description hereinafter sets forth the invention in the context of its preferred embodiments, in which a flexible cuvette or device is provided and used in the manner described in US-A-5 229 297. (Some of that disclosure is the same as that which appears in EP-A-0 381 501.)
  • In addition, the invention is useful regardless of whether PCR amplification is used or not, and regardless of the presence of all the features of that cuvette, provided that no more than one wash compartment is included with no more than one intervening wash step as a result.
  • As used herein, "wash" or "wash solution" means, a solution substantially free of capture, label and signal-forming reagents used in the other compartments, that is, in either the label compartment or the signalling material compartment.
  • The ability of the flexible cuvette described in US-A-5 229 297 to provide the elimination of the wash step without seriously resulting in non-specific signal, is not completely understood. It is thought, however, that it results from the construction of the cuvette in a way which causes a linear passage of a slug of each successive liquid such that the front of the "slug" acts to wash off unbound reagents left by the previous "slug". Any interaction which occurs at such "front" is of little or no consequence to the signal developed at the immobilized sites.
  • Furthermore, all of each slug of liquid passes over the detection site(s), improving the efficiency. The optional shear-thinning gel which can be added as described hereinafter enhances this capability, in that it appears to create a more viscous slug which retards backward migration of the components that are removed by the slug's front boundary.
  • Figure 1 illustrates one form of this invention, in which the wash compartment and wash step in between the reaction compartment and the label compartment has been eliminated. A reaction cuvette or device 10 comprises an inlet port 22 for injection of patient sample liquid, which connects via a passageway 21 to a PCR reaction compartment 26. A seal 46 temporarily blocks flow out of compartment 26. When seal 46 is broken, liquid feeds via a passageway 44 to a detection chamber 40 having sites 41 comprising, preferably, beads anchored in place which will complex with any targeted analyte passing them from compartment 26, and then with reagents coming from the other reagent compartments. Those other compartments are compartments 30, 32, 34, each feeding via passageways 48 and 50 to chamber 40. Each of those passageways is temporarily sealed at 56, and contains an appropriate reagent liquid.
  • The details of the chemicals useful in all the compartments, and at the sites 41, are explained in more detail in US-A-5 229 297. The wash compartment preferably comprises a buffer, surfactants, EDTA, NaCl, and other salts.
  • In accordance with this invention, the number of necessary compartments has been simplified. Hence:
       Compartment 26, in addition to the patient sample added by the user, preferably includes all the conventional reagents needed for PCR amplification, optionally kept in place by temporary seal 25. (The reagents can be pre-incorporated, or added with the patient sample as the latter is introduced.) The reagents include primers which are bound to one member of a binding pair, the other member of which appears in compartment 30 described below. A useful example of the binding member attached to a primer is biotin. (If present, Seal 25 is burst by injecting sample.)
  • Compartment 30 comprises, preferably, a label such as an enzyme bound to a complexing agent, such as avidin, which is a member of a binding pair, the other member of that pair being bound to a primer which becomes part of a targeted analyte during amplification in the reaction compartment 26 as described above. Hence, a useful reagent in compartment 30 is streptavidin horseradish peroxidase (hereinafter, SA-HRP). The other member of that binding pair is then biotin.
  • Labels other than enzymes are also useful. For example, fluorescent, radioactive, and chemiluminescent labels are also well-known for such uses. Chemiluminescent labels also preferably use a compartment 34 containing signalling reagent, discussed below for enzyme labels.
  • Compartment 32 preferably comprises a wash solution as the reagent.
  • Compartment 34 preferably comprises signalling material, and any dye stabilizing agent which may be useful. Thus, for example, a useful reagent solution in compartment 34 is a solution of a leuco dye which is a conventional substrate for the enzyme of compartment 30. H₂O₂ and any shear-thinning gels are also included.
  • Compartment 42 is a waste-collecting compartment, optionally containing an absorbant.
  • Roller 60 exemplifies the exterior pressure means used to burst each of the compartments sequentially, to sequentially advance the contents of the respective compartment to detection chamber 40. Because all of the compartments and passageways remain sealed during the processing, no leakage out of the device occurs and carry-over contamination is prevented. Sealing of port 22 is achieved by folding corner 70 about fold line 72, so that hole 74 fits over port 22 and passageway 21 is pinched off. A closure cap is then used to keep corner 70 so folded.
  • A useful processor to process device 10 is shown in EP-A-0 402 994. Such a processor uses a support surface on which devices 10 are placed in an array, and pressure members, for example, rollers, are mounted in position to process each of the cuvettes in parallel. The rollers are journalled several to one or more axles for convenience, these axles being incrementally advanced by gearing. Preferably, the support surface is horizontal or tilted up to 15° from horizontal. Additionally, heaters can be optionally included, either in stationary form or carried with the rollers.
  • Thus, one and only one wash compartment 32 is used, to provide a wash step after incubation of the SA-HRP at the sites 41 of compartment 40, to remove any unbound SA-HRP. It is thought that no wash step or wash liquid needs to be provided between the respective sequential movements of the amplified nucleic acid material and the SA-HRP, to sites 41, for the reason that each reagent directed to the detection site is effectively washed out by the next reagent entering the station. It is surprising that the small volume in each compartment is adequate to do this.
  • Alternatively (not shown), the exact same structure of Figure 1 is useful but with the wash liquid being located only in compartment 30, so that the SA-HRP is now located in compartment 32. In this configuration, the method proceeds to directly interact the signalling material of compartment 34 with sites 41 immediately after incubation of the SA-HRP at those sites, with no intervening wash. The reasons why this can be done are those set forth for the previous embodiment.
  • In either of the embodiments, the wash compartment can be supplemented, if desired, with additional wash liquid. A convenient method of doing this, Figure 2, is to add a wash compartment adjacent to the first wash compartment, so that initially the first wash compartment is emptied to the detection site, and then the second wash compartment. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "A" is appended.
  • Thus, cuvette 10A involves the exact same features as in the embodiment of Figure 1, except that an additional temporarily-sealed compartment 36 of wash liquid is interposed between compartments 32A and 34A. Passageway 52 connects it to compartment 40A, after seal 56A of compartment 36 is burst.
  • Alternatively, a single wash compartment but with a greater volume of wash, can be used.
  • It is not necessary that there be any wash compartment or any wash step resulting, as shown in Figure 3. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "B" is appended.
  • Thus, Figure 3, cuvette 10B comprises all the features of the previously described embodiments, except there is no wash compartment at all. The only compartments are the thermal cycling reaction compartment 26B, the label-containing compartment 30B (with, for example, streptavidin horseradish peroxidase, and compartment 34B containing the signalling material, for example, H₂O₂, optionally a shear-thinning gel described immediately hereafter, and a leuco dye which reacts with the label enzyme to produce a dye. When seals 46B and 56B are burst sequentially by roller 60B, the contents empty via passageways 44B and 48B, respectively, into detection site 40B and then into waste compartment 42B.
  • In all of the embodiments, an optional ingredient for inclusion with the signalling material is an approximate 0.5% agarose solution, to stabilize color formation at the detection sites in the detection compartment. Agarose has the shear thinning behavior that its viscosity at about this concentration drops 270mPas (27 poise) between a shear rate of 1 to 10²s⁻¹ (more than 60% of its drop), and only another 30mPas (3 poise) for rates above 10²s⁻¹, when measured at 40°C. Other shear-thinning gels of similar viscosity behavior and low percentage concentration can also be used.
  • As noted above, it is not completely understood how the cuvette surprisingly allows the wash steps to be eliminated, when heretofore they were considered essential between the addition of either the amplified material or the label, and the next reagent, to the detection site. Figures 4A to 4C are included to help illustrate a postulated mechanism, using, for example, the embodiment of Figure 3. However, the same principal is believed to be operative in all embodiments.
  • What is shown is an enlarged detection site 41B, comprising immobilized beads as described in the aforesaid EP-A-0 381 051. At the stage shown in Figure 4A, the amplified target nucleic acid material with a biotin tail is shown as "∼∼∼B". Such material has already been hybridized to the beads. Additionally, the compartment containing the label SA-HRP has been emptied to that site. (SA-HRP is shown as "A*" as a labeled avidin.) Some of that SA-HRP has already bound to the biotin of the target, but some is shown as unbound or "loose" on the beads and on the surface of compartment 40B.
  • When the next compartment, containing signalling material such as leuco dye (shown as "L.D.") is burst, the leuco dye advances as a "slug" 100, Figure 4B. Its leading meniscus 102 approaches site 41B because of its motion, as shown by arrow 104. When "slug" 100 passes over site 41B, Figure 4C, it sweeps off the unbound previous reagent (the A*) at meniscus 102, leaving only the bound label to react at the trailing part of slug 100 to produce dye at site 41B. Because it is region 110 which is read or detected, any extraneous dye produced downstream (at meniscus 102) is irrelevant. Backwards migration of such extraneous dye to the detection site is further retarded by the use of the optional shear-thinning gel described above.
  • Examples
  • The following non-exhaustive examples will help illustrate the invention.
  • All examples and comparative examples had reagents prepared as follows, unless otherwise noted:
  • A. Preparation of an HUT/HIV analyte for evaluation:
  • HUT/AAV/78 cells containing one copy of HIV per cell were treated in a standard phenol chloroform extraction process to isolate the DNA, and the amount of DNA obtained was quantified on a spectrophotometer. The recovered DNA (100,000 copies HIV) was amplified by polymerase chain reaction (PCR) in a cocktail containing each of the primers identified below (1µM each), buffer [10mM magnesium chloride, 50mM tris(hydroxymethyl)aminomethane (TRIS), 50mM potassium chloride, and 0.1mg/ml gelatin], 1.5mM of each of dATP, dCTP, dGTP, and dTTP deoxynucleotide triphosphates, and 40 units of DNA polymerase obtained from Thermus aquaticus.
  • Two sets of primers were used, one set complementary to the ENV region, and one set complementary to the GAG region of the HUT/HIV DNA, as is known to be used in multiplexing. One primer in each set was biotinylated to facilitate detection.
  • Two tetraethylene glycol spacer groups were attached to the oligonucleotide according to the teaching of US-A-4 914 210.
  • The PCR protocol was carried out using 250µl of the above cocktail in the PCR reaction blisters of PCR analytical elements of the type described in EP-A-0 381 051 and US-A-5 299 297. More specifically, the cuvette 10C of Figure 7 was used. Parts similar to those previously described bear the same reference numeral with the letter "C" appended. Thus, compartments 26C, 30C, 32C, 36C and 34C; passageways 44C, 48C, 50C and 52C; detection site 40C, and waste compartment 42C were used as described above, except for the layout, or as noted hereinafter. For one thing, PCR amplification was done in a cuvette separate from the test cuvette 10C, with the amplified material being pooled and then injected into compartment 26C for consistency of results in all replicates, for example, 32 in Example 1.
  • A thermal cycling processor of the type described in EP-A-0 402 994 was used.
  • The target DNA was preheated to 90°C for 10s, then denatured at 96°C for 30s and cooled to 70°C for 60s to anneal primers and produce primer extension products. The latter two steps (heating at 96°C, then 70°C) were repeated for a total of 40 cycles. This PCR process was replicated 64 times, and the fluid containing the newly made PCR product was transferred from the 64 PCR blisters into a common vessel to create a pool of PCR product. Samples from this pool were diluted 1:20 in the PCR buffer described above for use in the tests described hereinafter.
  • B. Preparation of wash solution (where used):
  • A wash solution was prepared to contain 1% sodium decyl sulfate in phosphate buffered saline solution containing 10mmolar sodium phosphate, 150mmolar sodium chloride, and 1mmolar ethylenediaminetetraacetic acid, pH 7.4.
  • C. Preparation of streptavidin/horseradish peroxidase (SA-HRP) conjugate solution:
  • A conjugate of streptavidin and horseradish peroxidase obtained from Zymed Labs (San Francisco, CA) was diluted 1:8000 with casein (0.5%) in a phosphate buffer solution (pH 7.3) containing thimerosal preservative (0.01%).
  • D. Preparation of leuco dye composition:
  • A solution of 25 g of polyvinylpyrrolidone in 100ml of water was mixed with a solution of 0.20g of 4,5-bis(4-dimethylaminophenyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)imidazole blue-forming leuco dye in 1ml N,N-dimethylformamide and stirred for 1 hour. This was then added to a solution prepared by mixing 2.76g of monosodium phosphate, monohydrate dissolved in 1900ml of water, 0.2ml of diethylenetriaminepentaacetic acid solution (0.1M), and 1.51g of 4'-hydroxyacetanilide and adjusting to pH 6.82 with 50% sodium hydroxide solution. Then 2ml of 30% hydrogen peroxide was added and the mixture stirred to form a dye dispersion. Finally, 24.75ml of the resulting dye dispersion was mixed with 0.25ml of aqueous 25µM dimedone and 0.125g of agarose to produce a dye-forming composition containing 0.5% agarose. The total composition was heated and stirred at 80°C until the agarose dissolved, and then cooled to room temperature.
  • E. Preparation of probe reagents:
  • A poly[styrene-co-3-(p-vinylbenzylthio)propionic acid] (mole ratio 97.6:2.4, weight ratio 95:5, 1µm average diameter) aqueous polymer particle dispersion was prepared, and an oligonucleotide described hereinafter was covalently bound to one portion of the polymer particles, and another oligonucleotide was covalently bound to another portion of the polymer particles using the procedures described in US-A-5 149 737 and in EP-A-0 462 644. The oligonucleotides were linked to the polymer particles through two tetraethylene glycol spacers, a 3-amino-1,2-propanediol moiety, and a thymine base. Each oligonucleotide was appended to the polymer particles through the amino group of the 3-amino-1,2-propanediol moiety to form reagents by the procedures of US-A-4 962 029.
  • The polymer/oligonucleotide particle probes were mixed with a latex adhesive of poly(methyl acrylate-co-sodium 2-acrylamido-2-methylpropanesulfonate-co-2-acetoacetoxyethyl methacrylate) (90:4:6 weight ratio) at a dry weight ratio of particles to adhesive polymer of 4/0.1 (2.5% adhesive). The aqueous dispersion had a solids content of 4%.
  • These reagent formulations were used to prepare a series of analytical devices containing the reagents as capture probes in assays for HUT/HIV. The control reagent oligonucleotide sequence is a sequence from the HIV genome and was employed as a nonsense sequence. This nonsense probe should not capture any of the HUT/HIV analyte sequences, and consequently, no dye development should occur on the control reagents. The other probe reagent sequence was complementary to a sequence in the ENV region of the HUT/HIV DNA.
  • The above reagents were used to prepare a series of analytical elements (cuvettes), each having reagent compartments (one of which is a PCR reaction blister into which the sample analyte is first introduced) a detection compartment, and a waste reservoir. The analytical devices (or elements) were prepared by heating a sheet of poly(ethylene terephthalate)/polyethylene laminate (SCOTCHPAK™ 241, 3M Co.) at a forming station (or mold) to form an array of depressed areas (blisters) toward one side of the sheet, and a larger depressed area near the end, and at the other side of the sheet, to which a main channel ultimately leads, a main channel from the first blister to the last, and tributary channels from each blister to the main channel so that upon lamination to a cover sheet at a later time, the resulting cuvette had narrow channels leading from the depressed areas to a main channel analogous to the devices described in US-A-5 299 297. Each depressed area except the one at each end of the main channel was filled with an appropriate reagent composition. A cover sheet was laminated to form a cover over the depressed and channel areas, and sealed to create a burst seal between each depressed area (except the last one) and the channel leading from it to the main channel. First, however, the cover sheet was treated overall with corona discharge. The probe reagent formulations described above (Invention & Control) were then immediately deposited in four alternating spots on the treated surface, each spot having 0.9 to 1.1µl of formulation noted hereinafter, in a row. The disposed formulations were dried for 30s in a stream of air at room temperature while heating the opposite side of the support with an iron at about 95°C.
  • EXAMPLE 1: Wash Compartments Only Between Label Compartment and Signalling Material Compartment
  • To demonstrate the embodiment of Figure 2, 16 replicates were prepared. The blisters of each one of the sheets in the 16 replicates prepared above were filled with reagents in the example tests as follows:
    Blister (Figure 7) Reagent
    26C Reserved for injection of analyte (190-210µl)
    30C SA-HRP conjugate (∼350µl)
    32C Wash solution (∼235µl)
    36C Wash solution (∼350µl)
    34C Leuco dye (∼235µl)
    (Thus, extra wash material was supplied, but effective only to separate blister 5 from blister 2, and not effective to separate blister 2 from blister 1.)
  • As a comparative example akin to those shown in EP-A-0 381 501 (the "stop solution" compartment having been omitted, a step clearly unnecessary for prompt readings), another set of 16 replicate cuvettes were prepared identical to Example 1, except that the positions of the first wash and the SA-HRP conjugate in blisters 2 and 3 and the amounts of each were reversed, that is, 350µl of wash solution and 235µl of SA-HRP solution were used.
  • The cover sheet was then laminated and sealed in three steps. First, the sandwich was pressed and sealed by heating at about 149°C only around the blisters containing the reagent solutions and around the waste blister. The formation of the sample-receiving PCR blister, including burst seals, and the channels was completed by heating the test pack between appropriately shaped heating jaws at about 163°C. The third step was the formation of perimeter seals around the test pack, and resealing all blister perimeter seals using a top plate temperature of 199°C while the bottom plate remained at ambient temperature. The channels and blisters formed in the completed test pack (or element) were located so that passage of a roller across the portion of the element containing the reagent blisters would sequentially burst the seals of the blisters and force the reagent from each blister into and along an exit channel to the main channel leading to the area containing the capture probes. The finished element was inverted so that the cover sheet containing the capture probe spots (deposits) is the bottom of the finished element with the probe deposits properly aligned in the main channel to form a detection station. The four probe spots were located in different positions of the main channel in several samples.
  • A last waste compartment located at the end of the main channel was larger than the others and fitted with an absorbent to be a reservoir for waste fluids, for both Example 1 and the Comparative Example.
  • The completed cuvettes of Example 1 and the Comparative Example were used to evaluate the reagent formulations as follows:
       A blister in each test device was filled (190-210µl) with a 20X dilution of the PCR product described above and processed as follows:
  • Example 1
  • The analyte was preheated to 95°C for 120s and its blister rolled to break the seal and advance the solution to the detection station (probe deposits). The analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the SA-HRP conjugate in the second blister was preheated to 65°C. The conjugate blister was rolled, the seal broken, and the solution directed to the detection area to displace the analyte. After 5min, the third blister containing the first wash solution preheated to 55°C was broken and the wash directed to the detection station and held there for 5min while the second wash solution was preheated to 55°C. Then the blister containing the second wash solution was broken and the wash directed to the detection station. Finally, the blister containing the dye signal-forming composition was rolled without preheating, and the seal broken, and the composition directed to the detection station where the color scores were read after a 5min incubation period using a color chart as described hereinbelow. The color scores are recorded in Table I and presented graphically in Figure 5A.
  • The Comparative Example
  • The blister containing the analyte in each element was preheated to about 95°C for 120s and then rolled to break the seal and advance the solution to the area containing the four immobilized deposits of probe reagents, that is, the two control probes and the two HUT/HIV probes deposited with adhesive. The analyte and probe reagents were hybridized in the detection station at 42°C for 5min, while the blister containing the wash solution was preheated to 55°C. Then the wash solution blister was rolled to break the seal and direct the wash solution into the detection area to clean out the main channel and to remove unbound analyte from the detection area. Then, without preheating, the seal of the streptavidin/horseradish peroxidase conjugate blister was rolled and broken and the solution directed to the detection area where it binds to the immobilized biotinylated analyte over a 5min period. During this time, the second wash composition was preheated to 55°C, and the seal of the blister was then broken with the roller and directed to the detection station where it displaced the unbound label. Finally, the seal of the dye signal-forming composition in the last blister was broken with the roller, and the fluid directed to the detection station where it displaced the second wash solution. Dye formation on the probe deposits was allowed to proceed for 5 minutes before reading color density scores. The color of each probe deposit was evaluated by comparison of the wet dye density with a color chart where 0 is no density and 10 is the highest density. The color scores are recorded in Table II and presented graphically in the graph of Figure 5B.
  • (The letters "LTR" and "ENV" of Tables I and II represent, respectively, the control nonsense probe deposits and the probe deposits complementary to the ENV region of the HIV genome in the analyte. These represent each of the 4 bead sites in the detection compartment. Left to right, the first bead encountered by flowing liquid was "LTR". The second was "ENV"; third, "LTR", and finally the last, "ENV" in the right hand column.) TABLE I
    Example 1 - HIV
    REPLICATE LTR ENV LTR ENV
    1 0.5 7 0.5 6.5
    2 0 6.5 0 4
    3 0.5 6.5 0.5 6.5
    4 1 6.5 1 6.5
    5 1 6.5 1 6.5
    6 0.5 6.5 0.5 6
    7 0.5 5 0.5 5.5
    8 0.5 6.5 0.5 6
    9 1 5 1 4
    10 0.5 5 0.5 5
    11 0.5 7 0.5 6.5
    12 0.5 6 0.5 6
    13 0.5 7 0.5 6.5
    14 0.5 6 0.5 7
    15 0.5 2 0 2
    16 0.5 7 0.5 6.5
    Average 6.0 5.69
    TABLE II
    Comparative Example - HIV
    REPLICATE LTR ENV LTR ENV
    1 0.5 5 0.5 5.5
    2 0.5 2 0.5 6
    3 0.5 6.5 0.5 5.5
    4 1 6 1 6
    5 0.5 2 0.5 2
    6 1 7 1 6
    7 1 7 1 5
    8 1 7 1 6
    9 1 3 1 7
    10 1 7 1 6
    11 0.5 1 0.5 4
    12 1 7 0.5 6
    13 1 7 1 6.5
    14 0.5 6 1 4
    15 1 6.5 1 6
    16 1 7 1 5.5
    Average 5.44 5.44
  • As is readily apparent, particularly from a comparison of Figures 5A and 5B, the elimination of the wash step after hybridizing the amplified nucleic acid material to the detection site and before adding the label reagent, did not harm the results. Indeed, better results occurred. Quantitatively, this can also be seen by averaging the second and fourth beads "ENV" in Example 1 for all 16 replicates, and comparing those with the Comparative Example. For Example 1, the average was 6.0 and 5.69, whereas for the Comparative Example it was 5.44 in both cases.
  • The above results are not limited to a particular assay - they also occur when assaying for, for example, CMV (cytomegalovirus). It is for this reason that the oligonucleotide sequences have not been specifically identified as it is believed to be immaterial which assay is used to show that one or both washes can be eliminated.
  • It has been shown that results comparable to those of Example 1 occur if the second wash compartment is omitted, to produce a cuvette as shown in Figure 1. That is, in such a cuvette a wash compartment and step occurs only between the label compartment and step (using SA-HRP) and the signalling material compartment and step (using a leuco dye and H₂O₂).
  • Similarly, it has been shown that such a 4-compartment cuvette with only one wash compartment, but located between the reaction compartment used to amplify the nucleic acid material, and the label compartment, produces results which are comparable to the conventional construction having a wash compartment (and step) after each of the reaction compartment (hybridizing step) AND the label compartment (labeling step).
  • EXAMPLE 2: Comparison of the Cuvettes of Example 1 with Cuvettes Containing no Wash Solutions
  • Two sets of PCR analytical cuvettes were prepared by the procedures of Example 1 with the following exceptions:
    1. A third probe composition was prepared by the procedures of Example 1 to contain a sequence complementary to a sequence from the GAG region of the HUT/HIV DNA.
    2. Only one spot (deposit) of each of the 3 probes was incorporated in each element, in the order of (1) new probe from the GAG region as described above, (2) control probe of Example 1, and (3) reagent probe of Example 1.
    3. One set of cuvettes was 5-blister cuvettes in the reverse wash format of Example 1 (SA-HRP conjugate in the second blister and wash in the third blister), and the cuvettes in that set were processed as described in Example 1.
    4. The second set of cuvettes used only 3 reagent compartments and no wash compartments, as shown in Figure 3. They contained the same compositions, including the analyte composition from the pool, and same amounts as the corresponding compositions in the first set of elements of Example 1 (the set with the conventional wash format), and the blisters were in the following order:
    Blister (Figure 7) Content
    26C PCR analyte
    30C SA-HRP
    32C Dye-forming detection composition
  • The remaining blisters or compartments were left empty.
  • The cuvettes in the second set were processed as follows:
       The analyte in the PCR blister was preheated to 95°C for 120s, and the blister was rolled to break the seal and direct the analyte to the 3 probe deposits in the detection station. Hybridization at 42°C was allowed to proceed for 5min while the SA-HRP solution in the second blister was preheated to 65°C. The second blister was then rolled to break the seal and the solution directed through the channels to the detection station. The conjugate was incubated over the detection station for 5min, then the blister containing the dye-forming detection dispersion was rolled without preheating to break the seal and direct the dispersion to the detection station to displace the SA-HRP. After 5min incubation of the dye dispersion in the detection station, the color scores were read using a color chart as in Example 1. The color scores for both sets of elements are recorded in Tables IIA and IIB and are presented graphically in the Graphs of Figures 6A and 6B, respectively.
  • The data show that the 3-blister cuvette configuration gives positive signals comparable to those of the 5-blister, wash cuvette format of Example 1; however, with slightly elevated signals on the nonsense (control) beads. This can be reduced or eliminated in the 3-blister configuration by using a larger volume of the dye-forming detection dispersion. The 3-blister configuration allows for use of less reagents, a smaller unit manufacturing cost, less cuvette storage space, shorter processing times, and a smaller, less complex processor. TABLE IIA
    5-Blister as with Example 1
    REPLICATE GAG ENV LTR
    1 7 7 0.5
    2 7 7 1
    3 7.5 7 1
    4 7.5 7 0.5
    5 7 7 1
    TABLE IIB
    3-Blister Data
    REPLICATE GAG ENV LTR
    1 7 7 2
    2 7.5 7 2
    3 7 7 2.5
    4 7.5 7 2.5
  • The invention disclosed herein may be practised in the absence of any element which is not specifically disclosed herein.

Claims (10)

  1. A method of detecting amplified nucleic acid material by hybridizing such material to a detection site comprising at least one immobilized probe, labeling the hybridized and now-immobilized nucleic acid material by bringing to the detection site a label which is or activates a signalling material to produce a signal, and thereafter adding the signalling material to the detection site to produce a detectable signal,
       characterized in that either the labeling step is used directly after the hybridizing step without requiring a wash step in between, or the adding step is used directly after the labeling step without requiring a wash step in between.
  2. A method according to claim 1, and further including a step of washing the detection site with wash liquid only between the step of hybridizing the nucleic acid material and the step of labeling with the label.
  3. A method according to claim 1, and further including a step of washing the detection site with wash liquid only between the steps of labeling with the label and adding the signalling material.
  4. A method according to claim 1, wherein both the labeling step is used directly after the hybridizing step without a separate wash step in between, and the adding step is used directly after the labeling step without a separate wash step in between.
  5. A method according to any one of claims 1 to 4, wherein the label is an enzyme.
  6. A method according to claim 1, further including the step of transferring the amplified material to the detection site prior to the step of hybridizing.
  7. A device (10; 10A; 10B; 10C) for amplifying and detecting nucleic acid material by using at least one target strand as a template, the device (10; 10A; 10B; 10C) comprising:-
       a reaction compartment (26; 26A; 26B; 26C) for amplifying a sample of nucleic acid material;
       a detection site (40, 41; 40A, 41A; 40B; 40C) for detecting amplified nucleic acid material;
       storage compartments (30, 32, 34; 30A, 32A, 34A, 36; 30B, 34B; 30C, 32C, 34C, 36C) containing a label and signalling material effective to generate, in combination, a detectable signal, and
       passageways (44, 48, 50; 44A, 48A, 50A, 52; 44B, 48B; 44C, 48C, 50C, 52C) for fluidly connecting the reaction compartment (26; 26A; 26B; 26C) and storage compartments (30, 32, 34; 30A, 32A, 34A, 36; 30B, 34B; 30C, 32C, 34C, 36C) with the detection site (40, 41; 40A, 41A; 40B; 40C);
       characterized in that the device (10; 10A; 10B; 10C) further includes no more than one wash compartment (32; 36) containing a wash liquid substantially free of capture, label, and signal-forming reagents used in the storage or reaction compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C), and no more than one passageway (48; 52) connecting the wash compartment (32; 36) to the detection site (40, 41; 40A, 41A; 40B; 40C) so that no more than one wash step is used in a sequence of steps comprising the emptying and moving of the contents of the reaction and storage compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C) to the detection site (40, 41; 40A, 41A; 40B; 40C).
  8. A device according to claim 7, wherein the device (10B; 10C) is free of any wash compartment containing a wash liquid substantially free of capture, label, and signal-forming reagents used in storage or reaction compartments.
  9. A device according to claim 7, wherein all of the compartments (26, 30, 32, 34; 26A, 30A, 32A, 34A, 36; 26B, 30B, 34B; 26C, 30C, 32C, 34C, 36C), detection site (40, 41; 40A, 41A; 40B; 40C), and passageways (44, 48, 50; 44A, 48A, 50A, 52; 44B, 48B; 44C, 48C, 50C, 52C) are sealed against leakage to the exterior of the device (10; 10A; 10B; 10C) to prevent carry-over contamination.
  10. A device according to any one of claims 7 to 9, wherein the label is an enzyme.
EP19930202962 1992-10-23 1993-10-21 Nucleic acid material amplification and detection Expired - Lifetime EP0594260B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96568392A 1992-10-23 1992-10-23
US965683 1992-10-23
US979569 1992-11-20
US07/979,569 US5422271A (en) 1992-11-20 1992-11-20 Nucleic acid material amplification and detection without washing

Publications (2)

Publication Number Publication Date
EP0594260A1 true EP0594260A1 (en) 1994-04-27
EP0594260B1 EP0594260B1 (en) 1998-03-18

Family

ID=27130480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19930202962 Expired - Lifetime EP0594260B1 (en) 1992-10-23 1993-10-21 Nucleic acid material amplification and detection

Country Status (6)

Country Link
EP (1) EP0594260B1 (en)
JP (1) JP3795540B2 (en)
DE (1) DE69317502T2 (en)
DK (1) DK0594260T3 (en)
FI (1) FI934669A (en)
TW (1) TW313588B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123980A2 (en) 2000-02-11 2001-08-16 Roche Diagnostics GmbH System for simple nucleic acid analysis
WO2007016693A2 (en) * 2005-08-02 2007-02-08 3M Innovative Properties Company Flexible apparatus and method for detecting an analyte
EP2138233A1 (en) * 2008-06-02 2009-12-30 Boehringer Ingelheim microParts GmbH Microfluid film structure for metering liquids
US7767447B2 (en) 2007-06-21 2010-08-03 Gen-Probe Incorporated Instruments and methods for exposing a receptacle to multiple thermal zones
WO2010126419A1 (en) * 2009-04-27 2010-11-04 Telefonaktiebolaget L M Ericsson (Publ) Methods and arrangements in a wireless communication system
US8012427B2 (en) 2005-08-02 2011-09-06 3M Innovative Properties Company Apparatus and method for detecting an analyte
US8780688B2 (en) 2009-04-27 2014-07-15 Telefonaktiebolaget Lm Ericsson (Publ) Methods and apparatus in a wireless communication system

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363339T1 (en) * 1998-05-01 2007-06-15 Gen Probe Inc STIRRING DEVICE FOR THE FLUID CONTENTS OF A CONTAINER
US8615368B2 (en) 2005-03-10 2013-12-24 Gen-Probe Incorporated Method for determining the amount of an analyte in a sample
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
JPWO2010106997A1 (en) 2009-03-19 2012-09-20 株式会社カネカ Nucleic acid detection method, kit and device
CN103543282A (en) 2010-07-23 2014-01-29 贝克曼考尔特公司 System for processing samples
US9046507B2 (en) 2010-07-29 2015-06-02 Gen-Probe Incorporated Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure
EP2678664B1 (en) 2011-02-24 2019-08-07 Gen-Probe Incorporated Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector
ES2729283T3 (en) 2011-11-07 2019-10-31 Beckman Coulter Inc Centrifugal and workflow system
ES2844324T3 (en) 2011-11-07 2021-07-21 Beckman Coulter Inc Robotic arm
BR112014010955A2 (en) 2011-11-07 2017-06-06 Beckman Coulter Inc system and method for processing samples
BR112014011035A2 (en) 2011-11-07 2017-06-13 Beckman Coulter, Inc. aliquot system and workflow
US8973736B2 (en) 2011-11-07 2015-03-10 Beckman Coulter, Inc. Magnetic damping for specimen transport system
KR20140091033A (en) 2011-11-07 2014-07-18 베크만 컬터, 인코포레이티드 Specimen container detection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318255A2 (en) * 1987-11-23 1989-05-31 EASTMAN KODAK COMPANY (a New Jersey corporation) Cuvette
EP0381501A2 (en) * 1989-02-03 1990-08-08 Eastman Kodak Company Containment cuvette for PCR and method of use
WO1992011390A1 (en) * 1990-12-17 1992-07-09 Idexx Laboratories, Inc. Nucleic acid sequence detection by triple helix formation
WO1992016659A1 (en) * 1991-03-21 1992-10-01 Eastman Kodak Company Element and method for nucleic acid amplification and detection using adhered probes
EP0572057A1 (en) * 1992-05-11 1993-12-01 Johnson & Johnson Clinical Diagnostics, Inc. PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408738B1 (en) * 1989-02-03 1994-01-19 Eastman Kodak Company Nucleic acid test article and its use to detect a predetermined nucleic acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318255A2 (en) * 1987-11-23 1989-05-31 EASTMAN KODAK COMPANY (a New Jersey corporation) Cuvette
EP0381501A2 (en) * 1989-02-03 1990-08-08 Eastman Kodak Company Containment cuvette for PCR and method of use
WO1992011390A1 (en) * 1990-12-17 1992-07-09 Idexx Laboratories, Inc. Nucleic acid sequence detection by triple helix formation
WO1992016659A1 (en) * 1991-03-21 1992-10-01 Eastman Kodak Company Element and method for nucleic acid amplification and detection using adhered probes
EP0572057A1 (en) * 1992-05-11 1993-12-01 Johnson & Johnson Clinical Diagnostics, Inc. PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123980A2 (en) 2000-02-11 2001-08-16 Roche Diagnostics GmbH System for simple nucleic acid analysis
US8012427B2 (en) 2005-08-02 2011-09-06 3M Innovative Properties Company Apparatus and method for detecting an analyte
WO2007016693A2 (en) * 2005-08-02 2007-02-08 3M Innovative Properties Company Flexible apparatus and method for detecting an analyte
WO2007016693A3 (en) * 2005-08-02 2007-05-31 3M Innovative Properties Co Flexible apparatus and method for detecting an analyte
US8480976B2 (en) 2007-06-21 2013-07-09 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
US8765367B2 (en) 2007-06-21 2014-07-01 Gen-Probe Incorporated Methods and instruments for processing a sample in a multi-chambered receptacle
US11235294B2 (en) 2007-06-21 2022-02-01 Gen-Probe Incorporated System and method of using multi-chambered receptacles
US7767447B2 (en) 2007-06-21 2010-08-03 Gen-Probe Incorporated Instruments and methods for exposing a receptacle to multiple thermal zones
US8048375B2 (en) 2007-06-21 2011-11-01 Gen-Probe Incorporated Gravity-assisted mixing methods
US8052929B2 (en) 2007-06-21 2011-11-08 Gen-Probe Incorporated Gravity-assisted mixing methods
US11235295B2 (en) 2007-06-21 2022-02-01 Gen-Probe Incorporated System and method of using multi-chambered receptacles
US8491178B2 (en) 2007-06-21 2013-07-23 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
US8735055B2 (en) 2007-06-21 2014-05-27 Gen-Probe Incorporated Methods of concentrating an analyte
US7780336B2 (en) 2007-06-21 2010-08-24 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
US10744469B2 (en) 2007-06-21 2020-08-18 Gen-Probe Incorporated Multi-chambered receptacles
US8784745B2 (en) 2007-06-21 2014-07-22 Gen-Probe Incorporated Methods for manipulating liquid substances in multi-chambered receptacles
US8828654B2 (en) 2007-06-21 2014-09-09 Gen-Probe Incorporated Methods for manipulating liquid substances in multi-chambered receptacles
US10688458B2 (en) 2007-06-21 2020-06-23 Gen-Probe Incorporated System and method of using multi-chambered receptacles
US9744506B2 (en) 2007-06-21 2017-08-29 Gen-Probe Incorporated Instruments for mixing the contents of a detection chamber
EP2138233A1 (en) * 2008-06-02 2009-12-30 Boehringer Ingelheim microParts GmbH Microfluid film structure for metering liquids
US9253777B2 (en) 2009-04-27 2016-02-02 Telefonaktiebolaget L M Ericsson (Publ) Methods and apparatus in a wireless communication system
US8780688B2 (en) 2009-04-27 2014-07-15 Telefonaktiebolaget Lm Ericsson (Publ) Methods and apparatus in a wireless communication system
WO2010126419A1 (en) * 2009-04-27 2010-11-04 Telefonaktiebolaget L M Ericsson (Publ) Methods and arrangements in a wireless communication system

Also Published As

Publication number Publication date
DE69317502D1 (en) 1998-04-23
TW313588B (en) 1997-08-21
DK0594260T3 (en) 1998-10-07
FI934669A (en) 1994-04-24
EP0594260B1 (en) 1998-03-18
JP3795540B2 (en) 2006-07-12
JPH06197797A (en) 1994-07-19
DE69317502T2 (en) 1998-08-20
FI934669A0 (en) 1993-10-22

Similar Documents

Publication Publication Date Title
US5422271A (en) Nucleic acid material amplification and detection without washing
EP0594260B1 (en) Nucleic acid material amplification and detection
EP0530357B1 (en) Element and method for nucleic acid amplification and detection using adhered probes
Findlay et al. Automated closed-vessel system for in vitro diagnostics based on polymerase chain reaction
US5380489A (en) Element and method for nucleic acid amplification and detection using adhered probes
US7932093B2 (en) One step oligochromatographic device and method of use
AU2010311138B2 (en) Device and apparatus
US6251660B1 (en) Devices and methods for detecting target molecules in biological samples
JP3034954B2 (en) Reaction tubes and methods of use to minimize contamination
WO1991015768A1 (en) Process and composition for performing dna assays
Verlander Detection of horseradish peroxidase by colorimetry
EP0572057A1 (en) PCR reagent composition, test kit and methods for amplification and detection with reduced nonspecific amplification of nucleic acids
EP0796917B1 (en) Vehicle for delivery of particles to a sample
EP1045030A2 (en) Amplification and detection of campylobacter jejuni and campylobacter coli
US6066455A (en) Method of detecting nucleic acids
EP0768519B1 (en) Container for staining of cells and tissues in combination with a roller and a support
US6485915B1 (en) Analytical element for species-specific detection of nucleic acids
EP2660334B1 (en) Positive control concept
US6197514B1 (en) Amplification and detection of Yersinia enterocolitica
WO2004042084A1 (en) Dry reagent strip and nucleic acid detection
Aubert et al. Accelerated detection of DNA on membranes by automated enzyme-linked immunofiltration assay

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IE IT LI LU NL SE

17P Request for examination filed

Effective date: 19941006

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CLINICAL DIAGNOSTIC SYSTEMS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.

17Q First examination report despatched

Effective date: 19960517

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE DK FR GB IE IT LI LU NL SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REF Corresponds to:

Ref document number: 69317502

Country of ref document: DE

Date of ref document: 19980423

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 79363

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.

Free format text: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US) -TRANSFER TO- JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20121031

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20121010

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20121018

Year of fee payment: 20

Ref country code: IE

Payment date: 20121010

Year of fee payment: 20

Ref country code: CH

Payment date: 20121012

Year of fee payment: 20

Ref country code: DE

Payment date: 20121017

Year of fee payment: 20

Ref country code: BE

Payment date: 20121018

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20121011

Year of fee payment: 20

Ref country code: IT

Payment date: 20121013

Year of fee payment: 20

Ref country code: GB

Payment date: 20121017

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20121010

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69317502

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20131021

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20131021

BE20 Be: patent expired

Owner name: *JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC.

Effective date: 20131021

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20131020

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20131022

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20131021

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20131020